Hence, a randomized phase 2 comparing two doses (5.4 mg/kg and 6.4 mg/kg once every 3 weeks) of trastuzumab deruxtecan, a monoclonal antibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2 or ERBB2), has been conducted in 152 patients with HER2-mutant non-small lung cancer (NSCLC). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.